Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 11NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Thoracic 7Gynecologic 6Other hematologic neoplasm 5Genitourinary 5Breast 5Lymphoid 3Tumor-Agnostic 2Other solid neoplasm 2Plasma cell 1Head & Neck 1Dermatologic 1

Conditions

Stomatitis 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Saline Solution × Head & Neck × Clear all
NCT01403064 2021-05-11

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

CSL Behring

Phase 2 Terminated
76 enrolled 25 charts
Head & Neck

Head and Neck Neoplasms, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡